11:08 AM EST, 11/10/2025 (MT Newswires) -- Atai Beckley ( ATAI ) said Monday its open-label extension of a phase 2b trial showed that an additional 12 milligram dose of BPL-003 nasal spray delivered rapid and sustained antidepressant effects for up to eight weeks.

The company said 63% of patients met response criteria and 48% remission criteria at week 8 after a second 12 mg dose in the trial's extension phase.

Atai Beckley ( ATAI ) added that the treatment was generally well-tolerated, with most side effects mild or moderate and occurring on the day of dosing.

The company said an end-of-phase 2 meeting has been scheduled with the Food and Drug Administration to finalize plans for a phase 3 program, expected to begin in Q2 2026.

Atai Beckley ( ATAI ) shares were 0.3% higher in recent trading.

Price: 4.39, Change: +0.02, Percent Change: +0.57